 The study developed a diagnostic panel consisting of three real-time reverse transcription PCR assays targeting the nucleocapsid gene of SARS-CoV-2, which was identified as the etiologic agent associated with coronavirus disease that emerged in late 2019. All assays demonstrated a linear dynamic range of eight orders of magnitude and an analytical limit of detection of five copies-slash-reaction of quantified RNA transcripts and one X 10-1.5 50% tissue-culture infectious dose-slash-ml of cell-cultured SARS-CoV-2. The assays performed comparably with nasal pharyngeal and oropharyngeal secretions, serum, and fecal specimens spiked with cultured virus. Results from all three assays were highly correlated during clinical specimen testing, and the Food and Drug Administration issued an emergency use authorization on February 4, 2020, to enable emergency use of this panel. This article was authored by Xiaoyan Lu, Li Juan Wang, Centelkumar K. Saktival and others. We are article.tv, links in the description below.